Program
deulumateperone
Also written as “ITI-1284”, “ITI-1284 10 mg” and “ITI-1284 20 mg”.
Its studies are mostly in Generalized Anxiety Disorder · Dementia · Psychotic Disorders, led by Johnson & Johnson.
Furthest: phase 3, since Sep 2, 20268 company-led studies, 6 open or runningNext primary completion: Mar 16, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 86 open or running | phase 3since Sep 2, 2026 | Mar 1, 2024 | Mar 16, 2027phase 2 · NCT06480383 |
- Named in Johnson & Johnson’s own pipeline as
ITI-1284
, phase 2, as of Oct 13, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 1, 2024First study: phase 1 study in Healthy VolunteersFirst studyNCT06299410 · 58 enrolled · United States
- Jun 24, 2024Phase 2 study in Generalized Anxiety DisorderNCT06480383 · 705 planned · United States, Bulgaria, Czechia and more
- Aug 2, 2024Phase 2 study in Psychotic DisordersNCT06540833 · 370 planned · United States, Bulgaria, Croatia and more
- Oct 18, 2024Phase 2 study in Agitation Associated With Alzheimer's DementiaNCT06651567 · 320 planned · United States, Bulgaria, Croatia and more
- Nov 20, 2024Phase 2 study in Generalized Anxiety DisorderNCT06701903 · 570 planned · United States, Bulgaria, Poland and more
- Jan 15, 2025Phase 1 study in Healthy VolunteersNCT06786286 · 8 enrolled · United Kingdom
- Sep 2, 20262 phase 3 studies in Generalized Anxiety DisorderPhase 3 reachedNCT07807865, NCT07856420
Ahead
- Mar 16, 2027Primary completion: phase 2 study in Generalized Anxiety DisorderNCT06480383
- Oct 14, 2027Primary completion: phase 2 study in Generalized Anxiety DisorderNCT06701903
- Dec 28, 2027Primary completion: phase 2 study in Agitation Associated With Alzheimer's DementiaNCT06651567
- Sep 30, 2028Primary completion: phase 2 study in Psychotic DisordersNCT06540833
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07856420Generalized Anxiety Disorder · United States | 3 | Recruiting | Sep 20, 2030 | 705 |
| NCT07807865Generalized Anxiety Disorder · United States | 3 | Recruiting | Feb 18, 2030 | 900 |
| NCT06786286Healthy Volunteers · United Kingdom | 1 | Completed | Mar 26, 2025 | 8 |
| NCT06701903Generalized Anxiety Disorder · United States, Bulgaria, Poland and more | 2 | Recruiting | Oct 14, 2027 | 570 |
| NCT06651567Agitation Associated With Alzheimer's Dementia · United States, Bulgaria, Croatia and more | 2 | Recruiting | Dec 28, 2027 | 320 |
| NCT06540833Psychotic Disorders · United States, Bulgaria, Croatia and more | 2 | Recruiting | Sep 30, 2028 | 370 |
| NCT06480383Generalized Anxiety Disorder · United States, Bulgaria, Czechia and more | 2 | Recruiting | Mar 16, 2027 | 705 |
| NCT06299410Healthy Volunteers · United States | 1 | Completed | Aug 18, 2026 | 58 |
How it is read
Names in the registry
- “ITI-1284”, 3 entries
- “ITI-1284 10 mg”, 3 entries
- “ITI-1284 20 mg”, 3 entries
- “JNJ-99245354”, 1 entry
- “[14C]-ITI-1284”, 1 entry
Conditions, from the studies’ own filings
- Generalized Anxiety Disorder, 4 studies
- Dementia, 1 study
- Psychotic Disorders, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.